ArticleFrontiers in oncology2026
Delineation of molecular subtypes based on pathway activation signatures reveals intrinsic tumor heterogeneity and pan-cancer shared features.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purposes: Individual molecular features are insufficient to elucidate the complex biological properties of pan-cancer. Accordingly, this study performed pan-cancer molecular subtyping based on pathway activation signatures to dissect the heterogeneity and commonality across malignancies. Methods: Transcriptomic data for 7,138 pan-cancer samples were retrieved from TCGA database for molecular subtyping. In parallel, transcriptomic data for 597 cell lines and drug sensitivity data for 269 lines were obtained from CCLE database for drug sensitivity analysis, and transcriptomic profiles of 16 in-house cell lines were incorporated for combined analysis. Results: Using unsupervised clustering, we classified pan-cancer into four distinct molecular subtypes based on the activity of 43 key cancer-related pathways. C1 was enriched for upregulated pathways involved in oncogenic signaling, cellular processes-related and immune pathways. C2 was characterized by upregulated activation of metabolic and DNA damage response (DDR) pathways. C3 displayed upregulated activity of metabolic, DDR and immune pathways. C4 showed elevated activity of oncogenic signaling, cellular processes-related, and DDR pathways. Notably, compared with C2 and C4, C1 and C3 displayed enhanced immune score, increased CD8+T cell infiltration and higher expression of genes involving in antigen processing and presentation, immunogenic cell death and immune checkpoint. C3 demonstrated the most favorable overall survival and the lowest proportion of progressive/stable disease patients, followed by C1, whereas C2 and C4 were associated with inferior clinical outcomes. C3 was susceptible to multiple agents, while C1 showed multidrug resistance. Moreover, Conclusions: Overall, our study defined four molecular subtypes based on the pathway activation profiles, with each subtype displaying unique features in pathway activation, clinical manifestations, treatment response, survival prognosis, immune microenvironment, and drug sensitivity. These findings may provide potential valuable insights for the precise diagnosis and treatment of cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.